Glaucoma's Changing Of The Guard
Executive Summary
Despite a crowded marketplace - with at least seven marketed drugs in at least three different classes -glaucoma remains a disease with a huge unmet need
You may also be interested in...
FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.
Glaucoma: Devices Go Eye-to-Eye With Drugs
This article was adapted from "In Glaucoma, Devices Go Eye-to-Eye with Drugs," in the September 2010 issue of Start-Up.
Glaucoma: Devices Go Eye-to-Eye With Drugs
This article was adapted from "In Glaucoma, Devices Go Eye-to-Eye with Drugs," in the September 2010 issue of Start-Up.